The U.S. Food and Drug Administration approved Scholar Rock’s injectable treatment Isembyld on Sept. 11 to improve motor function in adults and children with spinal muscular atrophy, marking the company’s first regulatory approval and sending shares up over 23% in after-market trading, according to Reuters.
FDA Grants First Regulatory Approval to Scholar Rock for Isembyld
The U.S. Food and Drug Administration granted approval on Friday for Scholar Rock’s Isembyld, making it the first muscle-targeted therapy designed to improve motor function for patients with spinal muscular atrophy (SMA) who have already received existing treatments, according to Reuters reporting by Sneha S K and Christy Santhosh.
Spinal muscular atrophy is a genetic disorder that damages motor neurons. According to the Muscular Dystrophy Association cited by Reuters, the condition causes progressive muscle weakness and problems with movement, breathing, and swallowing, affecting roughly 10,000 children and adults in the United States.
Market Impact and Financial Projections for Apitegromab
Following the regulatory announcement, Scholar Rock shares rose over 23% in after-market trading, according to Reuters. The company stated that Isembyld will be available in the coming days, though it did not immediately respond to requests for comment regarding pricing details.
Cantor analysts stated that Isembyld’s approval positions Scholar Rock as one of the strongest long-term growth stories in biotech, driven by potential geographic, indication, and product line expansions, as reported by Reuters. Additionally, BMO Capital Markets analyst Evan Seigerman forecasts $2.1 billion in adjusted worldwide peak sales for the drug by 2035.
Mechanism of Action and Competitive Landscape
The FDA approval was based on late-stage clinical data showing that the therapy significantly improved motor function for patients compared with a placebo.
Existing SMA Treatments
With this approval, Isembyld enters a competitive market alongside established therapies. According to Reuters, it will compete with:
- Biogen’s Spinraza
- Novartis’ gene therapy Zolgensma
- Roche’s oral treatment Evrysdi
Scholar Rock has previously stated that it plans to use a U.S.-based manufacturing facility to produce Isembyld.
Did you know?
Frequently Asked Questions
What is Isembyld used for?
According to Reuters, Isembyld (apitegromab) is an injectable, muscle-targeted therapy approved to improve motor function in adults and children with spinal muscular atrophy who have been treated with existing therapies.
How does apitegromab work?
Who are Isembyld’s main competitors?
According to Reuters, Isembyld will compete with Biogen’s Spinraza, Novartis’ Zolgensma, and Roche’s Evrysdi.
Stay Updated on Biotech Developments
Explore more industry analyses and coverage of regulatory approvals by checking out our latest articles or subscribing to our newsletter.
Worth a look